Background Hyperglycaemia could substantially increase the risk of ischaemic heart disease in patients with type 2 diabetes. We investigated whether intensive lowering of glucose concentrations aff ects risk.
Introduction
People with type 2 diabetes have a two to three times higher incidence of ischaemic heart disease than people without diabetes, even when other risk factors are taken into account. 1, 2 Reasons for this diff erence are unclear. Diabetes, however, is defi ned on the basis of raised glucose concentrations. 3 As the incidence of ischaemic heart disease increases with increasing glycated haemoglobin A 1c (HbA 1c ) con centrations, 4 glucose concentrations might be an important contributing factor. This possibility is supported by the fi nding that 10 years of intensive compared with standard glucose-lowering therapy reduces the 20-year risk of myocardial infarction by 15% in people with newly diagnosed type 2 diabetes. 5 Additionally, a meta-analysis of four large trials showed 15% reduced incidence of total myocardial infarction (95% CI 6-24) during a mean follow-up period of 4·4 years. 6 The ACCORD trial was a large North American trial of intense versus standard glucose-lowering therapy in people with established type 2 diabetes and additional risk factors for cardiovascular disease. As previously reported the intervention had a non-signifi cant eff ect on the primary composite cardiovascular outcome. The incidence of non-fatal myocardial infarction, however, was decreased, whereas the risk of death, particularly from cardiovascular causes, was increased. The eff ect on cardiovascular mortality remains unexplained. Exploratory analyses have so far identifi ed no relation with severe hypoglycaemia, 7 the degree or speed of glucose lowering, 8 or other potential factors. [9] [10] [11] The reduced rate of ischaemic heart disease in ACCORD was not explored. Here we report the eff ects of the ACCORD glucose-lowering interventions on indices of ischaemic heart disease, including fatal and non-fatal myocardial infarction and unstable and new-onset angina, and the degree to which change in HbA 1c concentration accounts for any of these eff ects.
Methods

Design
The design and results of the ACCORD trial have been published previously. 12, 13 Briefl y, 10 251 men and women aged 40-79 years with established type 2 diabetes (mean duration 10 years), a mean gHbA 1c concentration of 67 mmol/mol (8·3%), and either previous cardiovascular events or risk factors for cardiovascular disease were recruited from 77 clinical centres in the USA and Canada. Participants were randomly allocated to either intensive glucose-lowering therapy, with a target HbA 1c concentration of less than 42 mmol/mol (6·0%), or to standard glucose-lowering therapy, with a target concentration of 53-63 mmol/mol (7·0-7·9%). The medications used to achieve these targets were the same in the two groups and included metformin, shortacting and long-acting insulins, sulfonylureas, meglitinides, thiazo lidinediones, acarbose, and incretins. Participants were concomitantly enrolled in either a blood pressure trial (intense vs standard reduction) 14 or a lipid trial (optimised statin therapy with or without fenofi brate vs placebo), 15 in a double two-by-two factorial design. Patients were followed up at least every 4 months to ensure therapeutic goals were met and maintained and to monitor outcomes and adverse eff ects. The study protocol was approved by the ethics committee of each study centre, and approved and monitored by an independent data safety and monitoring board. All participants provided written informed consent.
Outcomes
The prespecifi ed primary outcome of ACCORD was the fi rst occurrence of non-fatal myocardial infarction, nonfatal stroke, or cardiovascular death, defi ned as death that was unexpected or presumed to be due to cardiovascular disease, congestive heart failure, myocardial infarction, stroke, other cardiovascular disease, a study procedure, or arrhythmia. 12, 13 Secondary outcomes were as follows: death from any cause; the primary outcome plus fi rst occurrence of revascularisation or hospitalisation for heart failure; combined fi rst occurrences of cardiovascular death, non-fatal myocardial infarction, and unstable angina; any stroke; and any congestive heart failure. 15 Coronary revascularisation was defi ned as percutaneous coronary intervention, with or without a stent, or coronary artery bypass surgery. Unstable angina was defi ned as self-reported new, accelerated, or rest angina plus ischaemia on ECG, evidence of stenosis on angiography, or both, and new-onset angina was defi ned as the fi rst time an event was recorded on the case report form as new-onset exertional angina. Outcomes were adjudicated centrally by researchers unaware of treatment allocations.
Treatment transition
Intensive therapy was discontinued after the data safety and monitoring board detected increases in all-cause and cardiovascular mortality. Participants were switched to the standard regimen on Feb 5, 2008, after a mean follow-up period of 3·7 years (treatment transition). All participants continued to be followed up in the blood pressure and lipid trials for a mean period of 1·2 years.
Statistical analysis
All statistical analyses were done at the ACCORD coordinating centre with SAS (version 9.3). Continuous data were summarised as mean (SD), median (IQR), or number (%). Event rates were estimated as the number of events divided by the total person-years of follow-up, and expressed as the number per 100 person-years. Analyses were done according to intention to treat, with separate assessment for outcomes accrued between randomisation and treatment transition and those accrued from randomisation until the end of follow-up. Mean or median values for HbA 1c , LDL cholesterol, and creatinine concentrations in serum, blood pressure, 62 (7) 62 (7 and the use of cardioprotective drugs were calculated from the latest data collected before treatment transition and the end of follow-up. We used cumulative incidence plots for death as a competing risk 16 to estimate the cumulative proportions of participants who had each type of event during the two follow-up periods.
We adopted the approach of Fine and Gray 17 to fi t proportional subdistribution hazard models to survival data with competing risks and to estimate the hazard ratios (95% CI) for the two follow-up periods. These models included a term representing treatment assignment plus terms accounting for participation in the blood pressure or lipid trial, assignment to the intensive blood pressure intervention in the blood pressure trial, assignment to fenofi brate in the lipid trial, and the presence or absence of previous cardiovascular disease. We did an exploratory analysis to investigate whether any eff ects the glucose-lowering intervention had on analysed outcomes could be attributable to the change in HbA 1c achieved before treatment transition. Hazard ratios were recalculated taking into account HbA 1c concentration as a time-dependent covariate (ie, new results were obtained every 4 months). We took p values less than 0·05 to be signifi cant.
Role of the funding source
The funder of the study participated in the study design, data analysis, and data interpretation. The funder had no role in data collection or writing of this report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
No signifi cant diff erences were seen between groups for baseline characteristics, or for blood pressure, LDL cholesterol and creatinine concentrations, or use of cardiovascular drugs during follow-up (table). Patients were followed up for a mean of 3•7 years until the date of transition, and a mean of 4•8 years until the end of full follow-up. Greater numbers of all classes of glucoselowering drugs and combinations had been used in the intensive treatment group than in the standard group at the end of the active treatment period. 12 1263 ischaemic heart disease events were reported during the active period and 1619 during the entire follow-up period. Fewer participants in the intensive therapy group experienced a myocardial infarction, a non-fatal myocardial infarction, or the composite
Figure 1: Incidence and risk of ischaemic heart disease events, by follow-up period
The numbers for the composite outcome of any MI or unstable angina shown in the fi gure diff er from those in a previous report 12 owing to a typographical error; the numbers in the previous report should have referred to non-stroke cardiovascular death, non-fatal MI, or unstable angina. MI=myocardial infarction. 
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Intensive Standard outcome of any myocardial infarction or unstable angina than in the standard therapy group in both follow-up periods (fi gure 1). Compared with the standard therapy group, participants in the intensive therapy group were 20% less likely to have any myocardial infarction during the active treatment period and 16% less likely during the entire follow-up period (fi gure 1). Findings were similar for the composite ischaemic heart disease outcome of myocardial infarction, unstable angina, or coronary revascularisation (fi gure 1). Lower rates of coronary revascularisation alone or unstable angina alone were seen in the intensive group for the entire treatment period but not before treatment transition (fi gure 1). The intervention had no signifi cant eff ect on fatal myocardial infarction or new angina. Cumulative incidence curves for all outcomes were lower with intensive therapy in both follow-up periods (fi gure 2, appendix). The addition of the HbA 1c concentration measured during the active treatment period as a time-dependent covariate to the hazard analysis attenuated all the signifi cant hazard ratios to neutral and did not change the signifi cance of the non-signifi cant hazard ratios (fi gure 3).
Discussion
Intensive therapy was associated with signifi cant reductions in the 5-year incidence of ischaemic heart disease (13%), any myocardial infarction (16%), non-fatal myocardial infarction (19%), coronary revascularisation (16%), and unstable angina (19%). These analyses were not prespecifi ed in the ACCORD protocol, but our fi ndings are consistent with those from other large outcomes trials where intensive glucose-lowering therapy reduced the incidence of fatal and non-fatal myocardial infarction in patients with type 2 diabetes (panel). 6 That these eff ects were evident before treatment transition and increased during further follow-up are consistent with at least one other trial done in people with type 2 diabetes. 5 Moreover, the fi nding that adjustment for HbA 1c concentrations achieved before treatment transition rendered these eff ects non-signifi cant supports the hypothesis that the degree of glucose lowering or some closely related factor accounts for the eff ect of the intervention on ischaemic heart disease. Finally the eff ect was consistent across diff erent measures of ischaemic heart disease. Together with the evidence that individuals with genetic markers of hyperglycaemia have higher glucose con centrations and are more likely to develop cardiovascular disease than those without these markers, 18 these fi ndings suggest that rising glucose concentration is a modifi able risk factor for ischaemic heart disease.
The benefi cial eff ect of the intensive glucose-lowering intervention on ischaemic heart disease is at odds with the ACCORD fi nding of increased risk of death from cardiovascular causes compared with the standard intervention. It is also at odds with the observation that the intensive intervention did not reduce fatal myocardial infarction. A possible explanation for these discrepancies is suggested by the fi ndings of an epidemiological analysis of ACCORD, where much of the mortality in the intensive treatment group occurred in people whose HbA 1c concentrations did not decrease from baseline. 7 Therefore, individuals whose glucose levels do not fall in response to intensive intervention, presumably due to unknown behavioural or biological factors, might have been harmed by persistent but futile attempts to lower glucose concentrations. Alternatively, the mortality in ACCORD could have been a chance fi nding. 11 This possibility is supported by the inability so far to identify any specifi c reason for this outcome. 7, 8, 10 Additionally, some of the fatal myocardial infarctions might have been misclassifi ed as other cardiovascular deaths. Irrespective of the ex planation, the fact that more than 80% of the cardiovascular deaths were judged not to be attributable to a myocardial infarction, 12, 13 and the reduced risk of ischaemic heart disease events with the intensive glucose-lowering intervention, suggest that ischaemic heart disease might not be related to mortality in the ACCORD intensive therapy group.
Owing to this analysis not being planned, our fi ndings could be due to chance and, therefore, not reproducible. The large number of statistical tests and the overlap between the various indices of ischaemic heart disease potentially increase the risk of chance. Moreover, the low number of fatal myocardial infarctions does not provide enough power to clearly estimate the eff ect of the intervention on fatal ischaemic heart disease or to rule out the possibility of divergent eff ects on fatal compared with non-fatal ischaemic heart disease. Strengths of this analysis include the randomised design, the large number of nonfatal events, and the high ascertainment of outcomes.
Whereas our fi ndings suggest that glucose-lowering interventions can reduce the risk of ischaemic heart disease, they do not nullify the previous observation that the overall cardiovascular benefi ts of 3•7 years of intensive glycaemic control are outweighed by the risk of death. Nevertheless, they are consistent with the hypothesis that dyglycaemia is causally related to ischaemic heart disease and strongly indicate the need for further investigation of this relation.
